The Zhao Lab focuses on developing novel clinical biomarkers that predict response and resistance to specific therapies across cancers. These biomarkers can be used to better select which patients derive a benefit from treatment, which patients do not and can be spared potential toxicity, as well as monitor for emergence of resistance. It seeks to use advanced computational approaches and liquid biopsy technologies to better personalize the care of cancer patients.
Genitourinary
Michael Bassetti, MD, PhD
Dr. Bassetti is an associate professor in the Department of Human Oncology with a clinical focus on gastrointestinal cancers and research interests in MRI-guided radiation and immunotherapy. He has been developing the use of real-time MRI-guided radiation to reduce toxicity, maximize local control and improve patient outcomes. Additionally, he is involved in combining immunotherapies with anatomically targeted high-dose radiotherapy to improve the antigen specific T cell response.
Gregory Cooley, MD
Dr. Cooley is a clinical associate professor in the Department of Human Oncology (DHO). The DHO is one of the few centers in the region offering both low-dose-rate and high-dose-rate prostate brachytherapy. Two decades ago, prostate brachytherapy showed superior PSA control rates. With further advances in dosing, fractionation and MRI-based planning, results are even better.